System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Howard Sofen is an expert in Dermatology at University of California, Los Angeles (United States). As of October 2026, ScienceLeadR ranks Howard Sofen in the top 1% of experts worldwide for Psoriasis and Skin Diseases, Papulosquamous. Howard Sofen has authored 150 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 3 of them ongoing. SLR score: 828 (community average: 125). How the SLR is computed.

LeadR Profile

Howard Sofen University of California, Los Angeles United States
828 ScienceLeadR Reputation 828

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Immunology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1985 - 2026
Source: PubMed

David Geffen School of Medicine at UCLA

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 150

Citations

Citations: 10 198 1st author: 11 Last author: 7 Unique author: 1

Main journals

J Am Acad Dermatol 28
SKIN The Journal of Cutaneous Medicine 16
Br J Dermatol 14
J Eur Acad Dermatol Venereol 13
Ann Rheum Dis 7

Best Journals

N Engl J Med 7
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.
PMID 42163822 — sexually transmitted diseases, dermatitis, eczema, adolescent, dermatology, dermatitis, atopic, non-responder		Acta Derm Venereol20260
Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks.
PMID 42105056 — safety, immunoglobulin a, obesity, therapeutics, psoriasis		Dermatol Ther (Heidelb)20260
Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial.
PMID 41405882 — safety, pharmaceutical preparations, skin diseases, drug-related side effects and adverse reactions, pruritus, prurigo, therapeutics		JAMA Dermatol20251
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.
PMID 41350512 — signs and symptoms, psoriasis		Dermatol Ther (Heidelb)20250
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
PMID 41314226 — skin, cells, safety, dermatitis, drug-related side effects and adverse reactions, chills, therapeutics, dermatitis, atopic		Lancet Top journal20251

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 16
Phase 2 6
Phase 4 2
N/A 1

By status:

Completed 20
Recruiting 2
Active not recruiting 1
Suspended 1
Terminated 1

By type:

Interventional 24
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 23

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
This Study is a Non interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803 — registries, dermatitis, adolescent, therapeutics, dermatitis, atopic		N/ARecruiting2025
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1 antihistamines
NCT06868212 — chronic urticaria, injections, administration, oral, histamine antagonists, syringes, urticaria, multiple chronic conditions, tablets, solutions, therapeutics		Phase 3Active not recruiting2025
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198 — skin, safety, alopecia areata, hair diseases, skin diseases, hypotrichosis, pathological conditions, anatomical, therapeutics, child, alopecia, pharmacokinetics		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS